Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): de Bardeci, Mateo (AUTHOR); Greil, Waldemar (AUTHOR); Stassen, Hans (AUTHOR); Willms, Jamila (AUTHOR); Köberle, Ursula (AUTHOR); Bridler, René (AUTHOR); Hasler, Gregor (AUTHOR); Kasper, Siegfried (AUTHOR); Rüther, Eckart (AUTHOR); Bleich, Stefan (AUTHOR); Toto, Sermin (AUTHOR); Grohmann, Renate (AUTHOR); Seifert, Johanna (AUTHOR)
- Source:
European Archives of Psychiatry & Clinical Neuroscience. Feb2023, Vol. 273 Issue 1, p65-74. 10p. 3 Charts, 1 Graph.
- Additional Information
- Subject Terms:
- Abstract:
Dear Doctor Letters (DDLs, Direct Healthcare Professional Communications) from 2011 provided guidance regarding QTc-prolonging effects with risk of torsade de pointes during treatment with citalopram and escitalopram. This study examines the DDLs' effects on prescription behavior. Data from 8842 inpatients treated with citalopram or escitalopram with a primary diagnosis of major depressive disorder (MDD) were derived from a European pharmacovigilance study (Arzneimittelsicherheit in der Psychiatrie, AMSP) from 2001 to 2017. It was examined to what extent new maximum doses were adhered to and newly contraindicated combinations with QTc-prolonging drugs were avoided. In addition, the prescriptions of psychotropic drugs before and after DDLs were compared in all 43,480 inpatients with MDD in the data set. The proportion of patients dosed above the new limit decreased from 8 to 1% in patients ≤ 65 years and from 46 to 23% in patients > 65 years old for citalopram versus 14–5% and 47–31% for escitalopram. Combinations of es-/citalopram with other QTc-prolonging psychotropic drugs reduced only insignificantly (from 35.9 to 30.9%). However, the proportion of patients with doses of quetiapine > 150 mg/day substantially decreased within the combinations of quetiapine and es-/citalopram (from 53 to 35%). After the DDLs, prescription of citalopram decreased and of sertraline increased. The DDLs' recommendations were not entirely adhered to, particularly in the elderly and concerning combination treatments. This might partly be due to therapeutic requirements of the included population. Official warnings should consider clinical needs. [ABSTRACT FROM AUTHOR]
- Abstract:
Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.